Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.33 USD | -2.92% | -2.10% | +0.43% |
05-09 | Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M | MT |
Evolution of the average Target Price on Mersana Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Mersana Therapeutics, Inc.
JPMorgan Chase | |
Truist Securities | |
Wedbush | |
Guggenheim | |
Citigroup | |
Baird | |
SVB Securities LLC | |
HC Wainwright | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- MRSN Stock
- Consensus Mersana Therapeutics, Inc.